Open AccessThe antinociceptive effects of a dual kappa-delta opioid receptor agonist in the mouse formalin test
Author(s) -
Esad Ulker,
Wisam Toma,
Alyssa White,
Rajendra Uprety,
Susruta Majumdar,
M. Imad Damaj
Publication year - 2020
Publication title -
behavioural pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 80
eISSN - 1473-5849
pISSN - 0955-8810
DOI - 10.1097/fbp.0000000000000541
Subject(s) - naltrindole , κ opioid receptor , pharmacology , agonist , opioid , medicine , nociception , antagonist , receptor , anesthesia , opioid receptor
Pain management is a challenging and unmet medical need. Despite their demonstrated efficacy, currently used opioid drugs and nonsteroidal anti-inflammatory drugs are frequently associated with several adverse events. The identification of new and safe analgesics is therefore needed. MP1104, an analogue of 3'-iodobenzoyl naltrexamine, is a potent nonselective full agonist at mu (MOR), kappa (KOR), and delta (DOR) opioid receptors, respectively. It was shown to possess potent antinociceptive effects in acute thermal pain assays without aversion in mice. In this study, we investigated MP1104 in the formalin test, a model of tonic pain. MP1104 (0.05, 0.1, and 1.0 mg/kg) reduced pain-like behaviors in phases I and II of the formalin test in male and female ICR mice. Pretreatment with KOR antagonist (norbinaltorphimine 10 mg/kg) and DOR antagonist (naltrindole 10 mg/kg) abolished the antinociceptive effects of MP1104 in the formalin test. These findings support the development of MP1104 for further testing in other pain models.